| Source | Evidence on protein | Close homologs |
|---|---|---|
| Cuervo et al. | no | yes: 0 |
| Hassani et al. | no | yes: 0 |
| Forrest at al. (metacyclic) | no | yes: 0 |
| Forrest at al. (procyclic) | no | yes: 0 |
| Silverman et al. | no | yes: 0 |
| Pissara et al. | no | yes: 15 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Pires et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Silverman et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Jamdhade et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| DeepLoc | ||
| SignalP6 | no | yes: 7, no: 4 |
| NetGPI | no | yes: 0, no: 11 |
Related structures:
AlphaFold database: A4I6H8
| Term | Name | Level | Count |
|---|---|---|---|
| GO:0006629 | lipid metabolic process | 3 | 12 |
| GO:0008152 | metabolic process | 1 | 12 |
| GO:0044238 | primary metabolic process | 2 | 12 |
| GO:0071704 | organic substance metabolic process | 2 | 12 |
| Term | Name | Level | Count |
|---|---|---|---|
| GO:0003824 | catalytic activity | 1 | 7 |
| GO:0004806 | triglyceride lipase activity | 5 | 7 |
| GO:0016298 | lipase activity | 4 | 7 |
| GO:0016787 | hydrolase activity | 2 | 7 |
| GO:0016788 | hydrolase activity, acting on ester bonds | 3 | 7 |
| GO:0052689 | carboxylic ester hydrolase activity | 4 | 7 |
| Leishmania | From | To | Domain/Motif | Score |
|---|---|---|---|---|
| CLV_C14_Caspase3-7 | 164 | 168 | PF00656 | 0.192 |
| CLV_NRD_NRD_1 | 104 | 106 | PF00675 | 0.289 |
| CLV_NRD_NRD_1 | 2 | 4 | PF00675 | 0.373 |
| CLV_PCSK_KEX2_1 | 2 | 4 | PF00082 | 0.373 |
| CLV_PCSK_SKI1_1 | 172 | 176 | PF00082 | 0.238 |
| CLV_PCSK_SKI1_1 | 228 | 232 | PF00082 | 0.350 |
| DEG_Nend_UBRbox_1 | 1 | 4 | PF02207 | 0.373 |
| DEG_SPOP_SBC_1 | 196 | 200 | PF00917 | 0.261 |
| DOC_MAPK_gen_1 | 216 | 225 | PF00069 | 0.401 |
| DOC_MIT_MIM_1 | 130 | 138 | PF04212 | 0.238 |
| DOC_PP4_FxxP_1 | 152 | 155 | PF00568 | 0.294 |
| DOC_USP7_MATH_1 | 12 | 16 | PF00917 | 0.381 |
| DOC_USP7_UBL2_3 | 102 | 106 | PF12436 | 0.291 |
| LIG_14-3-3_CanoR_1 | 177 | 185 | PF00244 | 0.331 |
| LIG_14-3-3_CanoR_1 | 2 | 8 | PF00244 | 0.416 |
| LIG_14-3-3_CanoR_1 | 207 | 217 | PF00244 | 0.533 |
| LIG_14-3-3_CanoR_1 | 228 | 234 | PF00244 | 0.392 |
| LIG_Actin_WH2_2 | 131 | 147 | PF00022 | 0.238 |
| LIG_BRCT_BRCA1_1 | 199 | 203 | PF00533 | 0.512 |
| LIG_BRCT_BRCA1_2 | 199 | 205 | PF00533 | 0.302 |
| LIG_FHA_1 | 107 | 113 | PF00498 | 0.283 |
| LIG_FHA_1 | 197 | 203 | PF00498 | 0.277 |
| LIG_FHA_1 | 40 | 46 | PF00498 | 0.351 |
| LIG_FHA_1 | 50 | 56 | PF00498 | 0.217 |
| LIG_LIR_Apic_2 | 151 | 155 | PF02991 | 0.294 |
| LIG_LIR_Gen_1 | 109 | 114 | PF02991 | 0.478 |
| LIG_LIR_Nem_3 | 109 | 113 | PF02991 | 0.383 |
| LIG_LIR_Nem_3 | 192 | 196 | PF02991 | 0.459 |
| LIG_LIR_Nem_3 | 88 | 92 | PF02991 | 0.338 |
| LIG_PDZ_Class_1 | 229 | 234 | PF00595 | 0.359 |
| LIG_PDZ_Wminus1_1 | 232 | 234 | PF00595 | 0.392 |
| LIG_PTB_Apo_2 | 156 | 163 | PF02174 | 0.304 |
| LIG_PTB_Apo_2 | 80 | 87 | PF02174 | 0.192 |
| LIG_PTB_Phospho_1 | 80 | 86 | PF10480 | 0.192 |
| LIG_SH2_CRK | 89 | 93 | PF00017 | 0.321 |
| LIG_SH2_SRC | 195 | 198 | PF00017 | 0.340 |
| LIG_SH2_STAP1 | 110 | 114 | PF00017 | 0.321 |
| LIG_SH2_STAP1 | 86 | 90 | PF00017 | 0.275 |
| LIG_SH2_STAT5 | 150 | 153 | PF00017 | 0.304 |
| LIG_SH2_STAT5 | 195 | 198 | PF00017 | 0.423 |
| LIG_SH3_3 | 183 | 189 | PF00018 | 0.316 |
| LIG_Sin3_3 | 122 | 129 | PF02671 | 0.227 |
| LIG_SUMO_SIM_anti_2 | 183 | 189 | PF11976 | 0.242 |
| LIG_WRC_WIRS_1 | 149 | 154 | PF05994 | 0.294 |
| MOD_CK1_1 | 208 | 214 | PF00069 | 0.560 |
| MOD_CK1_1 | 74 | 80 | PF00069 | 0.354 |
| MOD_CK1_1 | 88 | 94 | PF00069 | 0.241 |
| MOD_CK2_1 | 195 | 201 | PF00069 | 0.360 |
| MOD_CK2_1 | 74 | 80 | PF00069 | 0.447 |
| MOD_GlcNHglycan | 10 | 13 | PF01048 | 0.339 |
| MOD_GlcNHglycan | 219 | 222 | PF01048 | 0.589 |
| MOD_GSK3_1 | 3 | 10 | PF00069 | 0.518 |
| MOD_GSK3_1 | 70 | 77 | PF00069 | 0.252 |
| MOD_N-GLC_1 | 208 | 213 | PF02516 | 0.504 |
| MOD_NEK2_1 | 19 | 24 | PF00069 | 0.382 |
| MOD_NEK2_1 | 203 | 208 | PF00069 | 0.454 |
| MOD_NEK2_1 | 217 | 222 | PF00069 | 0.370 |
| MOD_NEK2_1 | 49 | 54 | PF00069 | 0.330 |
| MOD_NEK2_1 | 85 | 90 | PF00069 | 0.304 |
| MOD_PIKK_1 | 39 | 45 | PF00454 | 0.401 |
| MOD_PKA_2 | 176 | 182 | PF00069 | 0.310 |
| MOD_PKA_2 | 49 | 55 | PF00069 | 0.304 |
| MOD_Plk_1 | 19 | 25 | PF00069 | 0.442 |
| MOD_Plk_4 | 165 | 171 | PF00069 | 0.369 |
| MOD_Plk_4 | 54 | 60 | PF00069 | 0.218 |
| MOD_Plk_4 | 85 | 91 | PF00069 | 0.261 |
| MOD_SUMO_rev_2 | 139 | 147 | PF00179 | 0.238 |
| TRG_ENDOCYTIC_2 | 110 | 113 | PF00928 | 0.459 |
| TRG_ENDOCYTIC_2 | 89 | 92 | PF00928 | 0.343 |
| TRG_ER_diArg_1 | 1 | 3 | PF00400 | 0.396 |
| Protein | Taxonomy | Sequence identity | Coverage |
|---|---|---|---|
| A0A0S4IJE8 | Bodo saltans | 34% | 71% |
| A0A0S4J5D7 | Bodo saltans | 35% | 75% |
| A0A0S4JTA1 | Bodo saltans | 36% | 76% |
| A0A1X0NH29 | Trypanosomatidae | 38% | 96% |
| A0A1X0NHD7 | Trypanosomatidae | 37% | 100% |
| A0A1X0P001 | Trypanosomatidae | 39% | 68% |
| A0A3Q8IG97 | Leishmania donovani | 38% | 76% |
| A0A3S7X4C1 | Leishmania donovani | 99% | 100% |
| A2QSY5 | Aspergillus niger (strain CBS 513.88 / FGSC A1513) | 31% | 83% |
| A4HLK7 | Leishmania braziliensis | 47% | 70% |
| A4I6H7 | Leishmania infantum | 38% | 100% |
| B8NIB8 | Aspergillus flavus (strain ATCC 200026 / FGSC A1120 / IAM 13836 / NRRL 3357 / JCM 12722 / SRRC 167) | 35% | 83% |
| O42807 | Aspergillus niger | 31% | 83% |
| O42815 | Aspergillus tubingensis | 31% | 84% |
| O59952 | Thermomyces lanuginosus | 36% | 80% |
| P47145 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | 26% | 71% |
| P61869 | Penicillium cyclopium | 30% | 77% |
| P61870 | Penicillium camembertii | 30% | 77% |
| Q0CBM7 | Aspergillus terreus (strain NIH 2624 / FGSC A1156) | 34% | 83% |
| Q2UNW5 | Aspergillus oryzae (strain ATCC 42149 / RIB 40) | 35% | 83% |
| Q4Q6I0 | Leishmania major | 38% | 100% |
| Q9BHD5 | Leishmania major | 82% | 100% |
| Q9P979 | Aspergillus awamori | 31% | 83% |
| Q9XTR8 | Caenorhabditis elegans | 35% | 66% |
| V5B761 | Trypanosoma cruzi | 39% | 89% |